ConductScience.org, home

Paper374277

[Clinical efficacy, nephrotoxicity and ototoxicity of amikacin].

Federspil P and 5 others. Infection, 1979. Cited by 2 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. [Clinical efficacy, nephrotoxicity and ototoxicity of amikacin]. Papers, record 374277. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/374277

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
[Clinical efficacy, nephrotoxicity and ototoxicity of amikacin].
PubMed
Journal
Infection
PubMed
Year
1979
PubMed
Publication types
Case Reports, Clinical Trial, English Abstract, Journal Article
PubMed
Citations, by iCite
2
iCite
Relative citation ratio, by iCite
0.18
iCite
Revised in PubMed
2019-08-27
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Federspil PP
2Schindler KK
3Weich CC
4Tiesler EE
5Schätzle WW
6Ziegler MM

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AmikacinMajor topic
HearingMajor topic
KanamycinMajor topic
KidneyMajor topic
Vestibule, LabyrinthMajor topic
Adult
Aged
Chronic Disease
Clinical Trials as Topic
Drug Evaluation
Female
Humans
Male
Middle Aged
Time Factors
Urinary Tract Infections

Source PubMed

Download CSV of topics

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
1868906Comparative clinical studies of ototoxicity and nephrotoxicity of amikacin and gentamicin.Am J Med1977https://conductscience.org/library/papers/868906PubMed
2993623Amikacin in treatment of infections caused by gram-negative bacteria resistant to gentamicin and other aminoglycosides: clinical and bacteriologic results.J Infect Dis1976https://conductscience.org/library/papers/993623PubMed
3825585In vitro susceptibility of recently isolated gram-negative bacteria to gentamicin, sisomicin, tobramycin, and amikacin.J Infect Dis1976https://conductscience.org/library/papers/825585PubMed
41101761Amikacin therapy for severe gram-negative sepsis. Emphasis on infections with gentamicin-resistant organisms.Ann Intern Med1975https://conductscience.org/library/papers/1101761PubMed
5938024Ototoxicity of amikacin.Antimicrob Agents Chemother1976https://conductscience.org/library/papers/938024PubMed
6972282Pharmacokinetics and ototoxicity of gentamicin, tobramycin, and amikacin.J Infect Dis1976https://conductscience.org/library/papers/972282PubMed
7825591Susceptibility of current clinical isolates of Pseudomonas aeruginosa and enteric gram-negative bacilli to amikacin and other aminoglycoside antibiotics.J Infect Dis1976https://conductscience.org/library/papers/825591PubMed
84462458Amikacin (BB-K8) treatment of multiple-drug resistant Proteus infections.Antimicrob Agents Chemother1974https://conductscience.org/library/papers/4462458PubMed
9825588Susceptibility of recently isolated bacteria to amikacin in vitro: comparisons with four other aminoglycoside antibiotics.J Infect Dis1976https://conductscience.org/library/papers/825588PubMed
10868900Mechanisms of resistance to aminoglycosides.Am J Med1977https://conductscience.org/library/papers/868900PubMed
115596140Round table: optimal duration of antibiotic therapy in severe bacterial infections.Antimicrob Agents Chemother (Bethesda)1967https://conductscience.org/library/papers/5596140PubMed
12868909Amikacin therapy of gram-negative bacteremia.Am J Med1977https://conductscience.org/library/papers/868909PubMed
131200524Amikacin therapy for serious gram-negative bacillary infections.Ann Intern Med1975https://conductscience.org/library/papers/1200524PubMed
141017884[Ototoxicity of the aminoglycoside antibiotics (author's transl)].Infection1976https://conductscience.org/library/papers/1017884PubMed
15825589Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibiotic.J Infect Dis1976https://conductscience.org/library/papers/825589PubMed
16868907Comparison of amikacin and gentamicin in the treatment of urinary tract infections.Am J Med1977https://conductscience.org/library/papers/868907PubMed
1762814Amikacin, an aminoglycoside with marked activity against antibiotic-resistant clinical isolates.J Infect Dis1976https://conductscience.org/library/papers/62814PubMed
18868908Amikacin therapy for gram-negative septicemia.Am J Med1977https://conductscience.org/library/papers/868908PubMed
19586099Comparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients: a randomized prospective trail.Am J Med1977https://conductscience.org/library/papers/586099PubMed
205494465[Clinical ototoxicity of gentamycin and its reversibility].Arch Klin Exp Ohren Nasen Kehlkopfheilkd1970https://conductscience.org/library/papers/5494465PubMed

See all 22 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/374277

GET https://conductscience.org/api/papers/v1/374277/references?page=2